AI-generated from publicly available materials.The FDA's Predetermined Change Control Plan (PCCP) offers a pathway for medical device manufacturers to iterate on AI models post-clearance, yet few are taking advantage due to a lack of necessary MLOps infrastructure.
Recent findings indicate that only a small fraction of AI-enabled devices authorized by the FDA between 2023 and 2025 utilized the PCCP framework, which allows for pre-approved model updates. The underlying issue is not regulatory reluctance but rather the manufacturers' inability to commit to ongoing modification protocols without the requisite MLOps capabilities. Many firms have data and validation processes in place, but they lack the engineering infrastructure to support iterative updates effectively.
Moreover, traditional DevOps practices are insufficient for managing AI models, as they often overlook changes that can alter device behavior without any code modifications. This oversight highlights the necessity for MLOps as a distinct discipline, ensuring that model updates are tracked, validated, and integrated seamlessly into the overall product lifecycle. The FDA's guidelines emphasize the importance of maintaining data lineage and conducting thorough impact assessments, but these requirements cannot be met without robust automation and a well-structured data pipeline.
Ultimately, the ability to decouple AI models from the software that hosts them is crucial for fostering innovation. By treating models as independent, versioned artifacts, companies can facilitate more frequent updates without the complexities of full device releases. As competition intensifies, those with established pipelines and authorized PCCPs will likely gain a significant edge, underscoring the importance of building the necessary infrastructure before making regulatory commitments.